Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levodopa/Carbidopa in Angelman Syndrome
NCT03235037Completed
- Start
- Nov 2013
- Primary completion
- Feb 2019
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of levodopa in Angelman syndrome (AS). Primary endpoints: Improvement in motor control determined through composite measure- Tremor at 2 years, Improvement in motor control determined through composite measure- Ataxia at 2 years and 1 more. Started Nov 2013; status: completed.
02
Drugs
levodopa
03
Conditions
Angelman syndrome (AS)
Beyond the preview
Go deeper on NCT03235037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03235037.